Abstract：
What is this summary about? This is a plain language summary of an article published in the journal Brain. People with Alzheimer\'s disease may receive treatments that target amyloid-β – a protein in the brain that is one of the key characteristics of Alzheimer\'s disease when it is present in higher levels than normal. This article is about amyloid-related imaging abnormalities (ARIA), which can be adverse events for people with Alzheimer\'s disease receiving antibody treatments targeting amyloid-β (known as anti–amyloid-β antibody treatments). This article also discusses ways to identify and manage ARIA.ARIA are adverse events that happen due to amyloid-β buildup in the brain or following treatments targeting amyloid-β. ARIA are identified on MRI scans as swelling or bleeding in the brain, and people with ARIA do not typically have symptoms. In rare cases, ARIA can cause serious symptoms or lead to disability.What are the key takeaways? There are two types of ARIA: ARIA-E (swelling in the brain) and ARIA-H (bleeding in the brain).Presence of an APOE ε4 gene variant and exposure to anti–amyloid-β antibody treatments are major risk factors for ARIA.With the recent availability in the clinic of antibody treatments targeting amyloid-β, increased awareness is needed to identify, monitor and manage ARIA effectively.What were the main conclusions reported by the researchers? Uniform detection, monitoring and management of ARIA are essential in patients receiving antibody treatments targeting amyloid-β. To increase ARIA detection in clinical trials and clinical practice, the authors recommend the implementation of uniform imaging protocols and rigorous reporting standards.
摘要：
这是一篇发表在《大脑》杂志上的文章的简单语言摘要。患有阿尔茨海默病的人可能会接受针对淀粉样蛋白β的治疗，淀粉样蛋白β是大脑中的一种蛋白质，当它以高于正常水平的水平存在时，它是阿尔茨海默病的关键特征之一。本文是关于淀粉样蛋白相关的影像学异常（ARIA），对于接受针对β淀粉样蛋白的抗体治疗（称为抗β淀粉样蛋白抗体治疗）的阿尔茨海默病患者，这可能是不良事件。本文还讨论了识别和管理ARIA的方法。ARIA是由于脑中淀粉样蛋白-β积聚或靶向淀粉样蛋白-β的治疗后发生的不良事件。ARIA在MRI扫描中被确定为脑部肿胀或出血，ARIA患者通常没有症状。在极少数情况下,ARIA可引起严重症状或导致残疾。ARIA有两种类型：ARIA-E（脑部肿胀）和ARIA-H（脑部出血）。APOEε4基因变体的存在和暴露于抗淀粉样β抗体治疗是ARIA的主要危险因素。随着针对β淀粉样蛋白的抗体治疗在临床上的应用，需要提高认识来识别，有效监控和管理ARIA。研究人员报告的主要结论是什么？统一检测，ARIA的监测和管理对于接受针对β淀粉样蛋白的抗体治疗的患者至关重要.增加临床试验和临床实践中的ARIA检测，作者建议实施统一的成像方案和严格的报告标准.
